Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

Cancer Science

Volumn 99, Issue 4, 2008, Pages 653-658

  Itamochi, Hiroaki ^a   Kigawa, Junzo ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ETOPOSIDE; GEFITINIB; GLYCOPROTEIN P; IRINOTECAN; KI 67 ANTIGEN; LUNG RESISTANCE PROTEIN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; ONCOPROTEIN; PACLITAXEL; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA REPAIR; DRUG ACCUMULATION; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG INACTIVATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HYPERCALCEMIA; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOEMBOLISM; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 41349083323     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00747.x     Document Type: Review

References (69)

1. Schiller W. Mesonephroma ovarii. Am J Cancer 1939; 35: 1-21.
2. Scully RE. Recent progress in ovarian cancer. Hum Pathol 1970; 1: 73-98.
3. Serov SF, Scully RE, Sobin LH, eds. Histological Typing of Ovarian Tumours. (International Histological Classification No. 9). Geneva: World Health Organization, 1973; 17-54.
4. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971; 37: 1-9.
5. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-9.
6. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002; 84: 399-403.
7. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002; 100: 281-7.
8. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
9. Winter WE III, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-7.
10. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-8.
11. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
12. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157-63.
13. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-7.
14. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: A study of 59 cases. Gynecol Oncol 1989; 35: 199-203.
15. Ogawa S, Kaku T, Amada S et al. Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77: 298-304.
16. Silverberg SG. Ultrastructure and histogenesis of clear cell carcinoma of the ovary. Am J Obstet Gynecol 1973; 115: 394-400.
17. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: Its close association with malignant epithelial tumours. Histopathology 1997; 30: 249-55.
18. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S161-92.
19. Mizuno M, Kikkawa F, Shibata K et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006; 94: 138-43.
20. Andrews PA, Velury S, Mann SC, Howell SB. cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.
21. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35-43.
22. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-4.
23. Fujiwara Y, Sugimoto Y, Kasahara K et al. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 1990; 81: 527-35.
24. Kasahara K, Fujiwara Y, Nishio K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991; 51: 3237-42.
25. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999; 14: 123-31.
26. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302.
27. Kigawa J, Minagawa Y, Cheng X, Terakawa N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998; 4: 1737-41.
28. Itamochi H, Kigawa J, Sultana H et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002; 93: 723-8.
29. Ohishi Y, Oda Y, Uchiumi T et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 2002; 8: 3767-75.
30. Tsuda H, Ito YM, Ohashi Y et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 2005; 11: 6880-8.
31. Sharma M, He QY, Tomasz M. Effects of glutathione on alkylation and cross-linking of DNA by mitomycin C. Isolation of a ternary glutathione-mitomycin-DNA adduct. Chem Res Toxicol 1994; 7: 401-7.
32. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.
33. Xu Z, Chen ZP, Malapetsa A et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002; 13: 511-9.
34. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003; 9: 5299-305.
35. Claij N, te Riele H. Microsatellite instability in human cancer: A prognostic marker for chemotherapy? Exp Cell Res 1999; 246: 1-10.
36. Cai KQ, Albarracin C, Rosen D et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 2004; 35: 552-9.
37. Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27: 53-63; discussion 92-100.
38. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis. a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
39. Bellacosa A, de Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 280-5.
40. Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res 2002; 8: 2448-54.
41. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-100.
42. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-57.
43. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999; 18: 138-43.
44. Kim YC, Park KO, Kern JA et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22: 181-90.
45. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
46. Wang ZR, Liu W, Smith ST, Parrish RS, Young SR. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol 1999; 66: 140-8.
47. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994; 79: 551-5.
48. Marks JR, Davidoff AM, Kerns BJ et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-84.
49. Righetti SC, Della Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-93.
50. Ho ES, Lai CR, Hsieh YT et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001; 80: 189-93.
51. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001; 7: 2168-81.
52. Dimanche-Boitrel MT, Pelletier H, Genne P et al. Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 1992; 50: 677-82.
53. Itamochi H, Kigawa J, Akeshima R et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 2002; 62: 349-53.
54. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999; 85: 669-77.
55. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004; 92: 160-6.
56. Minagawa Y, Kigawa J, Irie T et al. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines. Jpn J Cancer Res 1997; 88: 1218-23.
57. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994; 85: 966-71.
58. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
59. Adachi S, Ogasawara T, Yamasaki N et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 1999; 29: 434-7.
60. Nishino K, Aoki Y, Amikura T et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005; 97: 893-7.
61. Itamochi H, Kigawa J, Kanamori Y et al. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: A potential treatment strategy. Mol Cancer Ther 2007; 6: 227-35.
62. Nahta R, Esteva FJ. HER-2-targeted therapy. lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-84.
63. Moran E, Mathews MB. Multiple functional domains in the adenovirus E1A gene. Cell 1987; 48: 177-8.
64. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 1990; 87: 4499-503.
65. Kawaguchi W, Itamochi H, Kigawa J et al. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3′-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci 2007; 98: 2002-8.
66. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-95.
67. Shen GH, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83: 196-203.
68. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25: 2902-8.
69. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006; 32: 875-86.